Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Authors:
Robert I Haddad Dana-Farber/Brigham and Women’s Cancer Center;

Search for other papers by Robert I Haddad in
Current site
Google Scholar
PubMed Close
 MD
,
Lindsay Bischoff Vanderbilt-Ingram Cancer Center;

Search for other papers by Lindsay Bischoff in
Current site
Google Scholar
PubMed Close
 MD
,
Douglas Ball The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

Search for other papers by Douglas Ball in
Current site
Google Scholar
PubMed Close
 MD
,
Victor Bernet Mayo Clinic Cancer Center;

Search for other papers by Victor Bernet in
Current site
Google Scholar
PubMed Close
 MD
,
Erik Blomain Stanford Cancer Institute;

Search for other papers by Erik Blomain in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Naifa Lamki Busaidy The University of Texas MD Anderson Cancer Center;

Search for other papers by Naifa Lamki Busaidy in
Current site
Google Scholar
PubMed Close
 MD
,
Michael Campbell UC Davis Comprehensive Cancer Center;

Search for other papers by Michael Campbell in
Current site
Google Scholar
PubMed Close
 MD
,
Paxton Dickson St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center;

Search for other papers by Paxton Dickson in
Current site
Google Scholar
PubMed Close
 MD
,
Quan-Yang Duh UCSF Helen Diller Family Comprehensive Cancer Center;

Search for other papers by Quan-Yang Duh in
Current site
Google Scholar
PubMed Close
 MD
,
Hormoz Ehya Fox Chase Cancer Center;

Search for other papers by Hormoz Ehya in
Current site
Google Scholar
PubMed Close
 MD
,
Whitney S. Goldner Fred & Pamela Buffett Cancer Center;

Search for other papers by Whitney S. Goldner in
Current site
Google Scholar
PubMed Close
 MD
,
Theresa Guo UC San Diego Moores Cancer Center;

Search for other papers by Theresa Guo in
Current site
Google Scholar
PubMed Close
 MD
,
Megan Haymart University of Michigan Rogel Cancer Center;

Search for other papers by Megan Haymart in
Current site
Google Scholar
PubMed Close
 MD
,
Shelby Holt UT Southwestern Simmons Comprehensive Cancer Center;

Search for other papers by Shelby Holt in
Current site
Google Scholar
PubMed Close
 MD
,
Jason P. Hunt Huntsman Cancer Institute at the University of Utah;

Search for other papers by Jason P. Hunt in
Current site
Google Scholar
PubMed Close
 MD
,
Andrei Iagaru Stanford Cancer Institute;

Search for other papers by Andrei Iagaru in
Current site
Google Scholar
PubMed Close
 MD
,
Fouad Kandeel City of Hope National Medical Center;

Search for other papers by Fouad Kandeel in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Dominick M. Lamonica Roswell Park Comprehensive Cancer Center;

Search for other papers by Dominick M. Lamonica in
Current site
Google Scholar
PubMed Close
 MD
,
Susan Mandel Abramson Cancer Center at the University of Pennsylvania;

Search for other papers by Susan Mandel in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Stephanie Markovina Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

Search for other papers by Stephanie Markovina in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Bryan McIver Moffitt Cancer Center;

Search for other papers by Bryan McIver in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Christopher D. Raeburn University of Colorado Cancer Center;

Search for other papers by Christopher D. Raeburn in
Current site
Google Scholar
PubMed Close
 MD
,
Rod Rezaee Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

Search for other papers by Rod Rezaee in
Current site
Google Scholar
PubMed Close
 MD
,
John A. Ridge Fox Chase Cancer Center;

Search for other papers by John A. Ridge in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Mara Y. Roth Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

Search for other papers by Mara Y. Roth in
Current site
Google Scholar
PubMed Close
 MD
,
Randall P. Scheri Duke Cancer Institute;

Search for other papers by Randall P. Scheri in
Current site
Google Scholar
PubMed Close
 MD
,
Jatin P. Shah Memorial Sloan Kettering Cancer Center;

Search for other papers by Jatin P. Shah in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Jennifer A. Sipos The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

Search for other papers by Jennifer A. Sipos in
Current site
Google Scholar
PubMed Close
 MD
,
Rebecca Sippel University of Wisconsin Carbone Cancer Center;

Search for other papers by Rebecca Sippel in
Current site
Google Scholar
PubMed Close
 MD
,
Cord Sturgeon Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

Search for other papers by Cord Sturgeon in
Current site
Google Scholar
PubMed Close
 MD
,
Thomas N. Wang O’Neal Comprehensive Cancer Center at UAB;

Search for other papers by Thomas N. Wang in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Lori J. Wirth Massachusetts General Hospital Cancer Center;

Search for other papers by Lori J. Wirth in
Current site
Google Scholar
PubMed Close
 MD
,
Richard J. Wong Memorial Sloan Kettering Cancer Center;

Search for other papers by Richard J. Wong in
Current site
Google Scholar
PubMed Close
 MD
,
Michael Yeh UCLA Jonsson Comprehensive Cancer Center; and

Search for other papers by Michael Yeh in
Current site
Google Scholar
PubMed Close
 MD
,
Carly J. Cassara National Comprehensive Cancer Network.

Search for other papers by Carly J. Cassara in
Current site
Google Scholar
PubMed Close
 MSc
, and
Susan Darlow National Comprehensive Cancer Network.

Search for other papers by Susan Darlow in
Current site
Google Scholar
PubMed Close
 PhD
Volume/Issue:
Volume 20: Issue 8
Online Publication Date:
Aug 2022
DOI:
https://doi.org/10.6004/jnccn.2022.0040
Restricted access

Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carcinoma is almost uniformly lethal, and iodine-131 imaging and radioactive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, Hürthle cell carcinoma).

Individual Disclosures for the NCCN Thyroid Carcinoma Panel
Individual Disclosures for the NCCN Thyroid Carcinoma Panel

  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Noone AM, Howlader N, Krapcho M, et al. SEER cancer statistics review, 1975-2015. Accessed July 6, 2022. Available at https://seer.cancer.gov/csr/1975_2015/

  • 2.

    Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7–33.

  • 3.

    Amin MB, Edge SB, Greene FL, et al., eds. AJCC Cancer Staging Manual, 8th ed. New York, NY: Springer International Publishing; 2017.

  • 4.

    Jonklaas J, Nogueras-Gonzalez G, Munsell M, et al. The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab 2012;97:E878–887.

  • 5.

    Stroup AM, Harrell CJ, Herget KA. Long-term survival in young women: hazards and competing risks after thyroid cancer. J Cancer Epidemiol 2012;2012:641372.

  • 6.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7–30.

  • 7.

    Ito Y, Higashiyama T, Takamura Y, et al. Long-term follow-up for patients with papillary thyroid carcinoma treated as benign nodules. Anticancer Res 2007;27:1039–1043.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Li N, Du XL, Reitzel LR, et al. Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980-2008. Thyroid 2013;23:103–110.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014;140:317–322.

  • 10.

    Wilhelm S. Evaluation of thyroid incidentaloma. Surg Clin North Am 2014;94:485–497.

  • 11.

    Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164–2167.

  • 12.

    Ito Y, Tomoda C, Uruno T, et al. Papillary microcarcinoma of the thyroid: how should it be treated? World J Surg 2004;28:1115–1121.

  • 13.

    Vergamini LB, Frazier AL, Abrantes FL, et al. Increase in the incidence of differentiated thyroid carcinoma in children, adolescents, and young adults: a population-based study. J Pediatr 2014;164:1481–1485.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Bann DV, Goyal N, Camacho F, et al. Increasing incidence of thyroid cancer in the Commonwealth of Pennsylvania. JAMA Otolaryngol Head Neck Surg 2014;140:1149–1156.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Aschebrook-Kilfoy B, Kaplan EL, Chiu BCH, et al. The acceleration in papillary thyroid cancer incidence rates is similar among racial and ethnic groups in the United States. Ann Surg Oncol 2013;20:2746–2753.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Schneider DF, Elfenbein D, Lloyd RV, et al. Lymph node metastases do not impact survival in follicular variant papillary thyroid cancer. Ann Surg Oncol 2015;22:158–163.

  • 17.

    Wang TS, Goffredo P, Sosa JA, et al. Papillary thyroid microcarcinoma: an over-treated malignancy? World J Surg 2014;38:2297–2303.

  • 18.

    Aschebrook-Kilfoy B, Grogan RH, Ward MH, et al. Follicular thyroid cancer incidence patterns in the United States, 1980-2009. Thyroid 2013;23:1015–1021.

  • 19.

    Aschebrook-Kilfoy B, Ward MH, Sabra MM, et al. Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid 2011;21:125–134.

  • 20.

    Yu GP, Li JC, Branovan D, et al. Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups. Thyroid 2010;20:465–473.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009;115: 3801–3807.

  • 22.

    Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 2009;18:784–791.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975-2014. Accessed July 6, 2022. Available at https://seer.cancer.gov/csr/1975_2014/

  • 24.

    Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 2012;366: 1674–1685.

  • 25.

    Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med 2012;366:1663–1673.

  • 26.

    Sherman SI. Thyroid carcinoma. Lancet 2003;361:501–511.

  • 27.

    Moreno MA, Agarwal G, de Luna R, et al. Preoperative lateral neck ultrasonography as a long-term outcome predictor in papillary thyroid cancer. Arch Otolaryngol Head Neck Surg 2011;137:157–162.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Sinclair CF, Duke WS, Barbu AM, et al. Laryngeal exam indications and techniques. In: Randolph GW, ed. The Recurrent and Superior Laryngeal Nerves. Cham, Switzerland: Springer International Publishing; 2016:17–29.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Liu W, Yan X, Cheng R. Continuing controversy regarding individualized surgical decision-making for patients with 1-4 cm low-risk differentiated thyroid carcinoma: a systematic review. Eur J Surg Oncol 2020;46:2174–2184.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann Surg Oncol 2005;12:81–89.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Davies L, Welch HG. Thyroid cancer survival in the United States: observational data from 1973 to 2005. Arch Otolaryngol Head Neck Surg 2010;136:440–444.

  • 32.

    Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16:1229–1242.

  • 33.

    Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007;246:375–381; discussion 381–384.

  • 34.

    Adam MA, Pura J, Gu L, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg 2014;260:601–605; discussion 605–607.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 1995;118:1131–1136; discussion 1136–1138.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Cady B. Our AMES is true: how an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg 1997;174:462–468.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Shaha AR. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Laryngoscope 2004;114: 393–402.

  • 38.

    Brito JP, Hay ID, Morris JC. Low risk papillary thyroid cancer. BMJ 2014;348:g3045.

  • 39.

    McHenry CR, Sandoval BA. Management of follicular and Hürthle cell neoplasms of the thyroid gland. Surg Oncol Clin N Am 1998;7: 893–910.

  • 40.

    Phitayakorn R, McHenry CR. Follicular and Hürthle cell carcinoma of the thyroid gland. Surg Oncol Clin N Am 2006;15:603–623.

  • 41.

    Chindris AM, Casler JD, Bernet VJ, et al. Clinical and molecular features of Hürthle cell carcinoma of the thyroid. J Clin Endocrinol Metab 2015;100:55–62.

  • 42.

    Cady B. Staging in thyroid carcinoma. Cancer 1998;83:844–847.

  • 43.

    Hay ID, Grant CS, Bergstralh EJ, et al. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998;124:958–964; discussion 964–966.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Anda Apiñániz E, Zafon C, Ruiz Rey I, et al. The extent of surgery for low-risk 1-4 cm papillary thyroid carcinoma: a catch-22 situation. A retrospective analysis of 497 patients based on the 2015 ATA Guidelines recommendation 35. Endocrine 2020;70:538–543.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Mazzaferri EL. Managing thyroid microcarcinomas. Yonsei Med J 2012;53:1–14.

  • 46.

    Matsuzu K, Sugino K, Masudo K, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg 2014;38:68–79.

  • 47.

    Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1–133.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Bilimoria KY, Zanocco K, Sturgeon C. Impact of surgical treatment on outcomes for papillary thyroid cancer. Adv Surg 2008;42:1–12.

  • 49.

    Ito Y, Miyauchi A, Kihara M, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 2014;24:27–34.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Oda H, Miyauchi A, Ito Y, et al. Incidences of unfavorable events in the management of low-risk papillary microcarcinoma of the thyroid by active surveillance versus immediate surgery. Thyroid 2016;26:150–155.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Tuttle RM, Fagin JA, Minkowitz G, et al. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol Head Neck Surg 2017;143:1015–1020.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Molinaro E, Campopiano MC, Pieruzzi L, et al. Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at a single Italian center. J Clin Endocrinol Metab 2020;105:e172–180.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Viola D, Materazzi G, Valerio L, et al. Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. J Clin Endocrinol Metab 2015;100:1316–1324.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Sippel RS, Robbins SE, Poehls JL, et al. A randomized controlled clinical trial: no clear benefit to prophylactic central neck dissection in patients with clinically node negative papillary thyroid cancer. Ann Surg 2020;272:496–503.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Ghossein R. Update to the College of American Pathologists reporting on thyroid carcinomas. Head Neck Pathol 2009;3:86–93.

  • 56.

    Mete O, Rotstein L, Asa SL. Controversies in thyroid pathology: thyroid capsule invasion and extrathyroidal extension. Ann Surg Oncol 2010;17:386–391.

  • 57.

    Ortiz S, Rodríguez JM, Soria T, et al. Extrathyroid spread in papillary carcinoma of the thyroid: clinicopathological and prognostic study. Otolaryngol Head Neck Surg 2001;124:261–265.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Pasieka JL, Thompson NW, McLeod MK, et al. The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy. World J Surg 1992;16:711–716; discussion 716–717.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Burge MR, Zeise TM, Johnsen MW, et al. Risks of complication following thyroidectomy. J Gen Intern Med 1998;13:24–31.

  • 60.

    Miccoli P, Antonelli A, Spinelli C, et al. Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident. Arch Surg 1998;133:89–93.

  • 61.

    Dralle H, Gimm O, Simon D, et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 1998;22:744–750; discussion 750–751.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Pattou F, Combemale F, Fabre S, et al. Hypocalcemia following thyroid surgery: incidence and prediction of outcome. World J Surg 1998;22:718–724.

  • 63.

    Hassanain M, Wexler M. Conservative management of well-differentiated thyroid cancer. Can J Surg 2010;53:109–118.

  • 64.

    Sosa JA, Bowman HM, Tielsch JM, et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998;228:320–330.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167–1214.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015;25:567–610.

  • 67.

    Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19:565–612.

  • 68.

    Gagel RF, Hoff AO, Cote GJ. Medullary thyroid carcinoma. In: Braverman LE, Utiger RD, Werner SC, et al., eds. Werner & Ingbar’s The Thyroid: A Fundamental and Clinical Text.9th ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2005:967–989.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Gagel RF, Cote GJ. Pathogenesis of medullary thyroid carcinoma. In: Fagin JA, ed. Thyroid Cancer. New York, NY: Springer; 1998:85–103.

  • 70.

    Gertner ME, Kebebew E. Multiple endocrine neoplasia type 2. Curr Treat Options Oncol 2004;5:315–325.

  • 71.

    Raue F, Frank-Raue K. Multiple endocrine neoplasia type 2: 2007 update. Horm Res 2007;68(Suppl 5):101–104.

  • 72.

    Moers AM, Landsvater RM, Schaap C, et al. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family. Am J Med 1996;101:635–641.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York, NY:Springer; 2010.

  • 74.

    Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer 1998;83:2638–2648.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Vitale G, Tagliaferri P, Caraglia M, et al. Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 2000;85:983–988.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Pacini F, Fontanelli M, Fugazzola L, et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1994;78:826–829.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Niccoli P, Wion-Barbot N, Caron P, et al. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. J Clin Endocrinol Metab 1997;82:338–341.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Özgen AG, Hamulu F, Bayraktar F, et al. Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. Thyroid 1999;9:579–582.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Horvit PK, Gagel RF. The goitrous patient with an elevated serum calcitonin--what to do? J Clin Endocrinol Metab 1997;82:335–337.

  • 80.

    Hodak SP, Burman KD. The calcitonin conundrum--is it time for routine measurement of serum calcitonin in patients with thyroid nodules? J Clin Endocrinol Metab 2004;89:511–514.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Kouvaraki MA, Shapiro SE, Perrier ND, et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005;15:531–544.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Samaan NA, Schultz PN, Hickey RC. Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 1988;67:801–805.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    O’Riordain DS, O’Brien T, Weaver AL, et al. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 1994;116:1017–1023.

  • 84.

    Wohllk N, Cote GJ, Bugalho MM, et al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1996;81:3740–3745.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Elisei R, Romei C, Cosci B, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 2007;92:4725–4729.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Elisei R, Alevizaki M, Conte-Devolx B, et al. 2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. Eur Thyroid J 2013;1:216–231.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Rosenthal MS, Diekema DS. Pediatric ethics guidelines for hereditary medullary thyroid cancer. Int J Pediatr Endocrinol 2011;2011:847603.

  • 88.

    Grubbs EG, Rich TA, Ng C, et al. Long-term outcomes of surgical treatment for hereditary pheochromocytoma. J Am Coll Surg 2013;216: 280–289.

  • 89.

    Carty SE, Cooper DS, Doherty GM, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid 2009;19:1153–1158.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 1984;63:319–342.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Machens A, Dralle H. Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg 2007;31:957–968.

  • 92.

    Learoyd DL, Gosnell J, Elston MS, et al. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations. Clin Endocrinol (Oxf) 2005;63:636–641.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Rich TA, Feng L, Busaidy N, et al. Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid 2014;24:1096–1106.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Niederle B, Sebag F, Brauckhoff M. Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease--a consensus statement of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg 2014;399:185–197.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86: 5658–5671.

  • 96.

    Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003;349: 1517–1525.

  • 97.

    Skinner MA, Moley JA, Dilley WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005;353: 1105–1113.

  • 98.

    Giuliani M, Brierley J. Indications for the use of external beam radiation in thyroid cancer. Curr Opin Oncol 2014;26:45–50.

  • 99.

    Brierley J, Sherman E. The role of external beam radiation and targeted therapy in thyroid cancer. Semin Radiat Oncol 2012;22:254–262.

  • 100.

    Brierley J, Tsang R, Simpson WJ, et al. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996;6:305–310.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Lutz ST, Lo SS, Chang EL, et al. ACR Appropriateness Criteria non-spine bone metastases. J Palliat Med 2012;15:521–526.

  • 102.

    Lo SS, Lutz ST, Chang EL, et al. ACR Appropriateness Criteria spinal bone metastases. J Palliat Med 2013;16:9–19.

  • 103.

    Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011;79:965–976.

  • 104.

    Gruber JJ, Colevas AD. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist 2015;20:113–126.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Haddad RI. How to incorporate new tyrosine kinase inhibitors in the treatment of patients with medullary thyroid cancer. J Clin Oncol 2013;31:3618–3620.

  • 106.

    Alemán JO, Farooki A, Girotra M. Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies. Endocr Relat Cancer 2014;21:R247–259.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31:3639–3646.

  • 108.

    Sherman SI. Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer. Oral Oncol 2013;49:707–710.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29:2660–2666.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010;95:2664–2671.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 111.

    Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30:134–141.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 112.

    Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 2020;383:825–835.

  • 113.

    Subbiah V, Hu MI, Wirth LJ, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol 2021;9:491–501.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 114.

    Kreissl MC, Bastholt L, Elisei R, et al. Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer: post hoc analysis from the ZETA trial. J Clin Oncol 2020;38:2773–2781.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 115.

    Thornton K, Kim G, Maher VE, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 2012;18:3722–3730.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Grande E, Kreissl MC, Filetti S, et al. Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther 2013;30:945–966.

  • 117.

    Schlumberger M, Elisei R, Müller S, et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol 2017;28: 2813–2819.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 118.

    Sherman SI, Clary DO, Elisei R, et al. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer 2016;122: 3856–3864.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 119.

    Traynor K. Cabozantinib approved for advanced medullary thyroid cancer. Am J Health Syst Pharm 2013;70:88.

  • 120.

    Ciampi R, Romei C, Ramone T, et al. Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. iScience 2019;20: 324–336.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 121.

    Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer 2014;14:173–186.

  • 122.

    Hu M, Subbiah V, Wirth LJ, et al. Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC) [abstract]. Ann Oncol 2020;31(Suppl 4):Abstract 1913O.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 123.

    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–247.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 124.

    Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21: 1353–1365.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 125.

    Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 2009;94:1493–1499.

  • 126.

    Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28:2323–2330.

  • 127.

    Kelleher FC, McDermott R. Response to sunitinib in medullary thyroid cancer. Ann Intern Med 2008;148:567.

  • 128.

    Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010;16:5260–5268.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 129.

    Bible KC, Suman VJ, Molina JR, et al. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab 2014;99:1687–1693.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 130.

    Schlumberger M, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clin Cancer Res 2016;22:44–53.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 131.

    Vuong HG, Ho ATN, Tran TTK, et al. Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: a systematic review and meta-analysis. Head Neck 2019;41:2823–2829.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 132.

    Orlandi F, Caraci P, Berruti A, et al. Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol 1994;5:763–765.

  • 133.

    Nocera M, Baudin E, Pellegriti G, et al. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Br J Cancer 2000;83:715–718.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 134.

    Schlumberger M, Abdelmoumene N, Delisle MJ, et al. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. Br J Cancer 1995;71:363–365.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 135.

    Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125–1132.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 136.

    Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613–2621.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 137.

    Vitale G, Fonderico F, Martignetti A, et al. Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer 2001;84:1586–1590.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 138.

    Ravaud A, de la Fouchardière C, Caron P, et al. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. Eur J Cancer 2017;76:110–117.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 139.

    Thomas L, Lai SY, Dong W, et al. Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist 2014;19:251–258.

  • 140.

    Klein Hesselink EN, Steenvoorden D, Kapiteijn E, et al. Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis. Eur J Endocrinol 2015;172:R215–225.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 141.

    Carhill AA, Cabanillas ME, Jimenez C, et al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab 2013;98: 31–42.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 142.

    Fallahi P, Ferrari SM, Vita R, et al. Thyroid dysfunctions induced by tyrosine kinase inhibitors. Expert Opin Drug Saf 2014;13:723–733.

  • 143.

    Cabanillas ME, Hu MI, Durand JB, et al. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res 2011;2011:985780.

  • 144.

    Gulati AP, Krantz B, Moss RA, et al. Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature. Oncology 2013;84:127–134.

  • 145.

    Gild ML, Bullock M, Robinson BG, et al. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol 2011;7:617–624.

  • 146.

    Santarpia L, Ye L, Gagel RF. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. J Intern Med 2009;266:99–113.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 147.

    Cakir M, Grossman AB. Medullary thyroid cancer: molecular biology and novel molecular therapies. Neuroendocrinology 2009;90:323–348.

  • 148.

    Cerrato A, De Falco V, Santoro M. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. J Mol Endocrinol 2009;43:143–155.

  • 149.

    Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28:767–772.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 150.

    Chatal JF, Campion L, Kraeber-Bodéré F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006;24:1705–1711.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 151.

    Salaun PY, Campion L, Bournaud C, et al. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement. J Nucl Med 2012;53:1185–1192.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 152.

    Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13:453–464.

  • 153.

    Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005;103:1330–1335.

  • 154.

    Gilliland FD, Hunt WC, Morris DM, et al. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 1997;79:564–573.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 155.

    Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012;22:1104–1139.

  • 156.

    Keutgen XM, Sadowski SM, Kebebew E. Management of anaplastic thyroid cancer. Gland Surg 2015;4:44–51.

  • 157.

    Thompson LD, Wieneke JA, Paal E, et al. A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer 2001;91:505–524.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 158.

    Serman SI. Anaplastic carcinoma: clinical aspects. In: Wartofsky L, Van Nostrand D, eds. Thyroid Cancer: A Comprehensive Guide to Clinical Management.2nd ed. Totowa, NJ: Humana Press; 2006:629–632.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 159.

    Asa SL, Bedard YC. Fine-needle aspiration cytology and histopathology. In: Clark OH, Noguchi S, eds. Thyroid Cancer: Diagnosis and Treatment. St. Louis, MO: Quality Medical Publishing; 2000:105–126.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 160.

    Bible KC, Kebebew E, Brierley J, et al. 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2021;31:337–386.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 161.

    Takashima S, Morimoto S, Ikezoe J, et al. CT evaluation of anaplastic thyroid carcinoma. AJR Am J Roentgenol 1990;154:1079–1085.

  • 162.

    Mani N, McNamara K, Lowe N, et al. Management of the compromised airway and role of tracheotomy in anaplastic thyroid carcinoma. Head Neck 2016;38:85–88.

  • 163.

    Shaha AR. Airway management in anaplastic thyroid carcinoma. Laryngoscope 2008;118:1195–1198.

  • 164.

    Untch BR, Olson JA Jr. Anaplastic thyroid carcinoma, thyroid lymphoma, and metastasis to thyroid. Surg Oncol Clin N Am 2006;15: 661–679.

  • 165.

    McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130:1028–1034.

  • 166.

    Stavas MJ, Shinohara ET, Attia A, et al. Short course high dose radiotherapy in the treatment of anaplastic thyroid carcinoma. J Thyroid Res 2014;2014:764281.

  • 167.

    Dumke AK, Pelz T, Vordermark D. Long-term results of radiotherapy in anaplastic thyroid cancer. Radiat Oncol 2014;9:90.

  • 168.

    Akaishi J, Sugino K, Kitagawa W, et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 2011;21:1183–1189.

  • 169.

    Burnison CM, Lim S. Multimodal approach to anaplastic thyroid cancer. Oncology (Williston Park) 2012;26:378–384; 390–398.

  • 170.

    Nachalon Y, Stern-Shavit S, Bachar G, et al. Aggressive palliation and survival in anaplastic thyroid carcinoma. JAMA Otolaryngol Head Neck Surg 2015;141:1128–1132.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 171.

    Saeed NA, Kelly JR, Deshpande HA, et al. Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer. Head Neck 2020;42:1031–1044.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 172.

    Pezzi TA, Mohamed ASR, Sheu T, et al. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: outcomes from the National Cancer Data Base. Cancer 2017;123:1653–1661.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 173.

    Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol 2018;36:7–13.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 174.

    Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731–739.

  • 175.

    Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271–282.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 176.

    Hong DS, Bauer TM, Lee JJ, et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol 2019;30:325–331.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 177.

    Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56:2155–2160.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 178.

    Brose MS, Albert CM, Waguespack SG, et al. Activity of larotrectinib in patients with advanced TRK fusion thyroid cancer [abstract]. Presented at the 88th Annual Meeting of the American Thyroid Association; October 3–7, 2018; Washington, DC.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 179.

    Capdevila J, Wirth LJ, Ernst T, et al. PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol 2020;38:2620–2627.

  • 180.

    Higashiyama T, Ito Y, Hirokawa M, et al. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 2010;20:7–14.

  • 181.

    Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 1998;8:715–726.

  • 182.

    Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Thyroid 2000;10:587–594.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 183.

    Sosa JA, Balkissoon J, Lu SP, et al. Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. Surgery 2012;152: 1078–1087.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 184.

    Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009;16:17–44.

  • 185.

    Savvides P, Nagaiah G, Lavertu P, et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid 2013;23:600–604.

  • 186.

    Perri F, Lorenzo GD, Scarpati GD, et al. Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options. World J Clin Oncol 2011;2:150–157.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 187.

    Deshpande HA, Gettinger SN, Sosa JA. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. Curr Opin Oncol 2008;20:19–24.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 188.

    Mooney CJ, Nagaiah G, Fu P, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 2009;19:233–240.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 189.

    Ha HT, Lee JS, Urba S, et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 2010;20:975–980.

  • 190.

    Bible KC, Suman VJ, Menefee ME, et al. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab 2012;97:3179–3184.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 191.

    Antonelli A, Fallahi P, Ulisse S, et al. New targeted therapies for anaplastic thyroid cancer. Anticancer Agents Med Chem 2012;12:87–93.

  • 192.

    Sosa JA, Elisei R, Jarzab B, et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid 2014;24:232–240.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 193.

    Chou A, Fraser S, Toon CW, et al. A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. Am J Surg Pathol 2015;39:652–659.

  • 194.

    Park G, Kim TH, Lee HO, et al. Standard immunohistochemistry efficiently screens for anaplastic lymphoma kinase rearrangements in differentiated thyroid cancer. Endocr Relat Cancer 2015;22:55–63.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 195.

    Pérot G, Soubeyran I, Ribeiro A, et al. Identification of a recurrent STRN/ALK fusion in thyroid carcinomas. PLoS One 2014;9:e87170.

  • 196.

    Kelly LM, Barila G, Liu P, et al. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci USA 2014;111:4233–4238.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 197.

    De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 2004;60:1137–1143.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 198.

    Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987;60:2372–2375.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 199.

    Mohebati A, Dilorenzo M, Palmer F, et al. Anaplastic thyroid carcinoma: a 25-year single-institution experience. Ann Surg Oncol 2014;21: 1665–1670.

  • 200.

    Derbel O, Limem S, Ségura-Ferlay C, et al. Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer 2011; 11:469.

  • 201.

    Wallin G, Lundell G, Tennvall J. Anaplastic giant cell thyroid carcinoma. Scand J Surg 2004;93:272–277.

  • 202.

    Smallridge RC. Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab 2012;97:2566–2572.

  • 203.

    Bhatia A, Rao A, Ang KK, et al. Anaplastic thyroid cancer: clinical outcomes with conformal radiotherapy. Head Neck 2010;32:829–836.

  • 204.

    Sun XS, Sun SR, Guevara N, et al. Chemoradiation in anaplastic thyroid carcinomas. Crit Rev Oncol Hematol 2013;86:290–301.

  • 205.

    Grégoire V, Mackie TR. State of the art on dose prescription, reporting and recording in intensity-modulated radiation therapy (ICRU report no. 83). Cancer Radiother 2011;15:555–559.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 206.

    International Commission on Radiation Units and Measurements. Report 83: prescribing, recording, and reporting photon-beam intensity- modulated radiation therapy (IMRT) [issue]. J ICRU 2010;10.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 207.

    Troch M, Koperek O, Scheuba C, et al. High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab 2010;95:E54–57.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 208.

    Heron DE, Karimpour S, Grigsby PW. Anaplastic thyroid carcinoma: comparison of conventional radiotherapy and hyperfractionation chemoradiotherapy in two groups. Am J Clin Oncol 2002;25: 442–446.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 209.

    Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 2011;21: 25–30.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 210.

    Nagaiah G, Hossain A, Mooney CJ, et al. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol 2011;2011:542358.

  • 211.

    Park JW, Choi SH, Yoon HI, et al. Treatment outcomes of radiotherapy for anaplastic thyroid cancer. Radiat Oncol J 2018;36:103–113.

  • 212.

    Rao SN, Zafereo M, Dadu R, et al. Patterns of treatment failure in anaplastic thyroid carcinoma. Thyroid 2017;27:672–681.

  • 213.

    Wang JR, Zafereo ME, Dadu R, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma. Thyroid 2019;29:1036–1043.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation